CareLit · DOI-Nachweis · Pneumologie
A phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)
DOI 10.1055/s-2007-973106
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, M McKeage, M Reck
ZeitschriftPneumologie
Ausgabe03/2007
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: DMXAA (AS1404) is a small-molecule vascular disrupting agent in trials for treatment of various tumours. This integrated phase Ib/II trial evaluated DMXAA in combination with carboplatin (C) and paclitaxel (P) in NSCLC. The phase Ib component confirmed 1200mg/m2 as the principal dose of DMXAA for the phase II part of the trial. Methods: Pat. had histologically confirmed stage IIIb or IV NSCLC previously untrea…
Zitieren
Zitierempfehlung
J von Pawel, M McKeage, M Reck (2007) A phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). Pneumologie (03). https://doi.org/10.1055/s-2007-973106
Mit CareLit weiterarbeiten